Skip to Content

Case Study

Direct Integration with Sponsor’s Medidata Rave System Saves Client 6 Weeks and $25,000

A global top-20 pharmaceutical company needed to conduct an 88-subject, Phase I, four-way crossover, thorough QT (TQT) study for a new drug with an endocrinology indication. The study required intensive Phase I ECG monitoring and required all protocol data to be transferred to the Sponsor’s Medidata Rave system.


Back to Resources

Ready to partner with Spaulding Clinical for your Phase I study?

Let’s Talk